cilostazol Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
644 73963-72-1

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • OPC 13013
  • cilostazol
  • cilostazole
  • pletal
  • OPC-13013
A quinoline and tetrazole derivative that acts as a phosphodiesterase type 3 inhibitor, with anti-platelet and vasodilating activity. It is used in the treatment of PERIPHERAL VASCULAR DISEASES; ISCHEMIC HEART DISEASE; and in the prevention of stroke.
  • Molecular weight: 369.47
  • Formula: C20H27N5O2
  • CLOGP: 3.53
  • LIPINSKI: 0
  • HAC: 7
  • HDO: 1
  • TPSA: 81.93
  • ALOGS: -4.06
  • ROTB: 7

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.20 g O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 0.00 mg/mL Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 7.73 ┬ÁM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD

Approvals:

DateAgencyCompanyOrphan
Jan. 15, 1999 FDA OTSUKA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Cerebral infarction 94.31 15.39 49 5537 23317 46657159
Ventricular fibrillation 40.40 15.39 22 5564 11474 46669002
Cardiac failure 35.93 15.39 46 5540 79902 46600574
Acinetobacter test positive 32.09 15.39 6 5580 82 46680394
Nikolsky's sign 30.48 15.39 6 5580 109 46680367
Cerebral haemorrhage 28.35 15.39 25 5561 28346 46652130
Anaemia 26.73 15.39 79 5507 255700 46424776
Urticaria vesiculosa 26.58 15.39 4 5582 12 46680464
Aortic dissection 25.90 15.39 9 5577 1583 46678893
Pyogenic granuloma 24.71 15.39 6 5580 296 46680180
Drug ineffective 24.67 15.39 27 5559 677811 46002665
Cardiac failure congestive 24.08 15.39 41 5545 91709 46588767
Beta-N-acetyl-D-glucosaminidase increased 22.73 15.39 4 5582 38 46680438
Interstitial lung disease 22.60 15.39 30 5556 53919 46626557
Ventricular tachycardia 21.18 15.39 17 5569 16950 46663526
Hepatic function abnormal 20.71 15.39 23 5563 34398 46646078
Haemorrhage subcutaneous 20.64 15.39 9 5577 2897 46677579
Gastrointestinal haemorrhage 19.54 15.39 34 5552 77339 46603137
Torsade de pointes 19.17 15.39 14 5572 12140 46668336
Parotid gland enlargement 18.97 15.39 6 5580 788 46679688
Blood urea increased 18.92 15.39 19 5567 25333 46655143
Subarachnoid haemorrhage 17.94 15.39 13 5573 11140 46669336
Blood pressure decreased 16.95 15.39 27 5559 57132 46623344
Acute leukaemia 16.85 15.39 6 5580 1132 46679344
Kounis syndrome 16.53 15.39 6 5580 1196 46679280
Liver disorder 16.03 15.39 21 5565 37225 46643251
Melaena 15.75 15.39 18 5568 27754 46652722
Enterobacter test positive 15.71 15.39 4 5582 240 46680236
Shock 15.62 15.39 16 5570 21829 46658647
Peripheral arterial occlusive disease 15.50 15.39 8 5578 3744 46676732

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Cerebral infarction 125.65 14.14 86 9108 26287 29916997
Hepatic function abnormal 68.49 14.14 74 9120 41871 29901413
Interstitial lung disease 60.39 14.14 83 9111 60114 29883170
Peripheral arterial occlusive disease 59.82 14.14 30 9164 5138 29938146
Haemorrhage subcutaneous 35.08 14.14 16 9178 2221 29941063
Altered state of consciousness 33.99 14.14 36 9158 19883 29923401
Sprue-like enteropathy 31.04 14.14 9 9185 338 29942946
Toxicity to various agents 29.31 14.14 9 9185 177174 29766110
Intermittent claudication 28.92 14.14 14 9180 2220 29941064
Thrombosis in device 25.53 14.14 15 9179 3511 29939773
Hemiplegia 25.42 14.14 19 9175 6642 29936642
Cerebral haemorrhage 25.22 14.14 40 9154 32847 29910437
Decreased appetite 24.58 14.14 101 9093 149809 29793475
Gastric ulcer haemorrhage 24.49 14.14 17 9177 5297 29937987
Lacunar infarction 24.37 14.14 14 9180 3141 29940143
Renal impairment 23.73 14.14 68 9126 84116 29859168
Haematochezia 22.71 14.14 39 9155 34183 29909101
Drug ineffective 22.63 14.14 44 9150 340343 29602941
Gastrointestinal haemorrhage 22.17 14.14 66 9128 83380 29859904
Cardiac failure 21.24 14.14 65 9129 83353 29859931
Cerebral hyperperfusion syndrome 21.13 14.14 5 9189 83 29943201
Pneumonia aspiration 19.94 14.14 39 9155 37741 29905543
Carotid artery stenosis 19.39 14.14 14 9180 4640 29938644
Thrombotic cerebral infarction 19.06 14.14 6 9188 299 29942985
Contrast encephalopathy 18.87 14.14 4 9190 39 29943245
Thalamus haemorrhage 18.73 14.14 8 9186 950 29942334
Gastric cancer 18.62 14.14 14 9180 4936 29938348
Peripheral artery occlusion 18.53 14.14 9 9185 1437 29941847
Depressed level of consciousness 18.43 14.14 38 9156 38184 29905100
Basal ganglia haematoma 17.41 14.14 4 9190 58 29943226
Acute myocardial infarction 17.13 14.14 45 9149 52894 29890390
Disseminated intravascular coagulation 17.04 14.14 27 9167 22144 29921140
Peripheral artery restenosis 16.87 14.14 3 9191 10 29943274
Fat embolism 16.71 14.14 5 9189 210 29943074
Arterial restenosis 16.16 14.14 4 9190 81 29943203
Peripheral vascular disorder 15.83 14.14 13 9181 5206 29938078
Drug eruption 15.81 14.14 23 9171 17503 29925781
Shock haemorrhagic 15.37 14.14 17 9177 9848 29933436
Hypoglycaemia 15.15 14.14 42 9152 50939 29892345
Chronic pigmented purpura 15.13 14.14 4 9190 106 29943178
Haemobilia 15.12 14.14 5 9189 292 29942992
Angioplasty 14.98 14.14 7 9187 1027 29942257
Liver disorder 14.86 14.14 30 9164 29692 29913592
Tachycardia 14.78 14.14 53 9141 73686 29869598
Transient ischaemic attack 14.51 14.14 27 9167 25173 29918111
Ventricular tachycardia 14.28 14.14 26 9168 23836 29919448
Blood pressure decreased 14.21 14.14 39 9155 47036 29896248
Venous haemorrhage 14.18 14.14 3 9191 29 29943255

Pharmacologic Action:

SourceCodeDescription
ATC B01AC23 BLOOD AND BLOOD FORMING ORGANS
ANTITHROMBOTIC AGENTS
ANTITHROMBOTIC AGENTS
Platelet aggregation inhibitors excl. heparin
FDA MoA N0000175086 Phosphodiesterase 3 Inhibitors
FDA EPC N0000175598 Phosphodiesterase 3 Inhibitor
MeSH PA D018927 Anti-Asthmatic Agents
MeSH PA D001993 Bronchodilator Agents
MeSH PA D002317 Cardiovascular Agents
MeSH PA D002491 Central Nervous System Agents
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D005343 Fibrinolytic Agents
MeSH PA D006401 Hematologic Agents
MeSH PA D018696 Neuroprotective Agents
MeSH PA D018373 Peripheral Nervous System Agents
MeSH PA D058987 Phosphodiesterase 3 Inhibitors
MeSH PA D010726 Phosphodiesterase Inhibitors
MeSH PA D010975 Platelet Aggregation Inhibitors
MeSH PA D020011 Protective Agents
MeSH PA D019141 Respiratory System Agents
MeSH PA D014665 Vasodilator Agents
CHEBI has role CHEBI:35523 bronchodilator agents
CHEBI has role CHEBI:35620 vasodilator
CHEBI has role CHEBI:48676 fibrin modulating agents
CHEBI has role CHEBI:50249 anticoagulante
CHEBI has role CHEBI:50427 platelet aggregation inhibitors
CHEBI has role CHEBI:50568 cyclic nucleotide phosphodiesterase inhibitor
CHEBI has role CHEBI:63726 neuroprotective agents

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Intermittent claudication indication 63491006 DOID:3669
Chronic heart failure contraindication 48447003
Kidney disease contraindication 90708001 DOID:557
Disease of liver contraindication 235856003 DOID:409

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
cGMP-inhibited 3',5'-cyclic phosphodiesterase A Enzyme INHIBITOR IC50 6.70 IUPHAR CHEMBL
Cytochrome P450 2C9 Enzyme IC50 5 DRUG MATRIX
cGMP-inhibited 3',5'-cyclic phosphodiesterase B Enzyme INHIBITOR IC50 6.42 IUPHAR

External reference:

IDSource
4021153 VUID
N0000148605 NUI
D01896 KEGG_DRUG
4021153 VANDF
C0055729 UMLSCUI
CHEBI:31401 CHEBI
CHEMBL799 ChEMBL_ID
DB01166 DRUGBANK_ID
D000077407 MESH_DESCRIPTOR_UI
2754 PUBCHEM_CID
7148 IUPHAR_LIGAND_ID
5680 INN_ID
N7Z035406B UNII
21107 RXNORM
14036 MMSL
60734 MMSL
7889 MMSL
d04382 MMSL
007339 NDDF
116087001 SNOMEDCT_US
395239000 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Cilostazol HUMAN PRESCRIPTION DRUG LABEL 1 0054-0028 TABLET 50 mg ORAL ANDA 27 sections
Cilostazol HUMAN PRESCRIPTION DRUG LABEL 1 0054-0044 TABLET 100 mg ORAL ANDA 27 sections
Cilostazol HUMAN PRESCRIPTION DRUG LABEL 1 0093-2064 TABLET 100 mg ORAL ANDA 28 sections
Cilostazol HUMAN PRESCRIPTION DRUG LABEL 1 0093-2065 TABLET 50 mg ORAL ANDA 28 sections
Cilostazol HUMAN PRESCRIPTION DRUG LABEL 1 0185-0123 TABLET 50 mg ORAL ANDA 29 sections
Cilostazol HUMAN PRESCRIPTION DRUG LABEL 1 0185-0223 TABLET 100 mg ORAL ANDA 29 sections
CILOSTAZOL HUMAN PRESCRIPTION DRUG LABEL 1 16590-285 TABLET 100 mg ORAL ANDA 22 sections
Cilostazol HUMAN PRESCRIPTION DRUG LABEL 1 50090-5329 TABLET 50 mg ORAL ANDA 28 sections
cilostazol HUMAN PRESCRIPTION DRUG LABEL 1 50268-176 TABLET 50 mg ORAL ANDA 20 sections
cilostazol HUMAN PRESCRIPTION DRUG LABEL 1 50268-177 TABLET 100 mg ORAL ANDA 20 sections
Cilostazol HUMAN PRESCRIPTION DRUG LABEL 1 54868-5411 TABLET 100 mg ORAL ANDA 16 sections
cilostazol HUMAN PRESCRIPTION DRUG LABEL 1 60505-2521 TABLET 50 mg ORAL ANDA 20 sections
cilostazol HUMAN PRESCRIPTION DRUG LABEL 1 60505-2522 TABLET 100 mg ORAL ANDA 20 sections
Cilostazol HUMAN PRESCRIPTION DRUG LABEL 1 68151-3844 TABLET 50 mg ORAL ANDA 26 sections
Cilostazol HUMAN PRESCRIPTION DRUG LABEL 1 68151-4123 TABLET 100 mg ORAL ANDA 26 sections
Cilostazol HUMAN PRESCRIPTION DRUG LABEL 1 70436-050 TABLET 50 mg ORAL ANDA 29 sections
Cilostazol HUMAN PRESCRIPTION DRUG LABEL 1 70436-051 TABLET 100 mg ORAL ANDA 29 sections
Cilostazol HUMAN PRESCRIPTION DRUG LABEL 1 70436-156 TABLET 50 mg ORAL ANDA 28 sections
Cilostazol HUMAN PRESCRIPTION DRUG LABEL 1 70436-157 TABLET 100 mg ORAL ANDA 28 sections
Cilostazol HUMAN PRESCRIPTION DRUG LABEL 1 70518-2200 TABLET 100 mg ORAL ANDA 28 sections
Cilostazol HUMAN PRESCRIPTION DRUG LABEL 1 70518-2208 TABLET 50 mg ORAL ANDA 28 sections
cilostazol HUMAN PRESCRIPTION DRUG LABEL 1 70518-2714 TABLET 100 mg ORAL ANDA 20 sections
Cilostazol HUMAN PRESCRIPTION DRUG LABEL 1 71610-037 TABLET 100 mg ORAL ANDA 29 sections
CILOSTAZOL HUMAN PRESCRIPTION DRUG LABEL 1 72189-116 TABLET 50 mg ORAL ANDA 16 sections